Nagasaki University and Astellas Pharma Inc. Launch Collaborative Research for Screening New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
Published: Mar 21, 2013
NAGASAKI, Japan & TOKYO--(BUSINESS WIRE)--The Nagasaki University ("Nagasaki University"; Nagasaki, Japan; President: Shigeru Katamine) and Astellas Pharma Inc. ("Astellas")(TOKYO:4503)(President and CEO: Yoshihiko Hatanaka) today announced that they have signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases ("NTDs") caused by dengue virus. This is the second execution of a collaborative research agreement on NTDs after the Nagasaki University and Astellas signed the previous one to discover new drugs for the treatment of NTDs caused by protozoan parasites on November 12, 2012.